Clindamycin Phosphate

Tolerability and safety

Irritation potential

Low

Allergen risk

Low

Pregnancy

Caution

About this ingredient

Clindamycin Phosphate is a topical antibiotic of the lincosamide class. A prodrug: the phosphate ester is inactive, and skin keratinocyte phosphatase hydrolyzes it to active clindamycin. In Spanish pharmacies it is prescription-only: Dalacin T (Pfizer) 1%, Zindaclin 1% gel, Dalacin C 1% lotion. Where applied. Mild-to-moderate inflammatory acne (papulopustular form). Concentration 1% in gel, lotion, solution, cream. Applied 1-2 times daily to affected areas. Course 8-12 weeks. Mechanism. Binds the 50S subunit of the Cutibacterium acnes (Propionibacterium acnes) bacterial ribosome, suppresses protein synthesis. Bacteriostatic effect. Additionally suppresses neutrophil chemotaxis to the inflammation focus – an anti-inflammatory effect independent of the antimicrobial one. Evidence base. AAD 2024 and Spanish AEDV 2023 recommend topical clindamycin as part of combination therapy for mild-moderate acne. Monotherapy efficacy is moderate: 40-60% inflammatory-lesion reduction in 12 weeks (Leyden 2007). Combined with 5% benzoyl peroxide (BPO) efficacy rises to 70-80% with reduced resistance risk (which is critical). Resistance controversy. Since the 2000s C. acnes resistance to clindamycin has been rising – already 30-50% of strains in Europe. AAD 2024 and AEDV 2023 ban clindamycin monotherapy – only in combination with BPO, azelaic acid, or retinoids (adapalene, tretinoin). Course duration – no more than 12 weeks. Safety. Skin systemic absorption is 5-10%. Locally: erythema, peeling, burning in the first 2 weeks in 5-15% of patients. Serious adverse effect – pseudomembranous colitis (C. difficile) – described in isolated cases with topical use, on predisposing background. Pregnancy and lactation – FDA category B. Topical clindamycin is allowed in pregnancy and lactation at standard concentrations. Acceptable in the 2nd-3rd trimesters. Do not apply to the nipple during breastfeeding – the infant may ingest. Therapy monitoring. At 8-12 weeks reassess effect with a dermatologist. Without improvement – switch to oral isotretinoin (severe acne), azelaic acid (mild alternative), benzoyl peroxide + retinoid. Not suitable for long-term, multi-year use due to resistance risk.

Frequently asked questions